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Atopic dermatitis (AD, eczema) is an
inflammatory skin condition that typi-
cally presents as erythema, scaling, and
urticaria (Weidinger and Novak, 2016).
Prevalence in the U.S. is approximately
10% and observed to be higher in
children than adults (Drucker et al.,
2017). Vitamin D supplementation has
been suggested for treatment, with
conflicting results reported in the liter-
ature (Bath-Hextall et al., 2012;
Hattangdi-Haridas et al., 2019). There
is evidence of an observational associ-
ation between AD and vitamin D,
where sufferers, especially children,
have been found to have reduced
levels, with greater deficiency seen in
severe AD (Palmer, 2015).
Traditional observational studies can
be biased because of confounding and
reverse causation. Mendelian random-
ization (MR) is a useful tool to investi-
gate the presence and direction of a
causal relationship. Exposure-
associated SNPs are used as a proxy
for the exposure of interest to investi-
gate the causal effect on an outcome
(Budu-Aggrey and Paternoster, 2019).
MR has been previously used to inves-
tigate the causal effect of vitamin D (25-
hydroxycholecalciferol [25-OHD])
levels on AD risk (Manousaki et al.,
2017). In this study, we extend this
analysis using GWAS data from the
most current vitamin D meta-analysis
(Manousaki et al., 2020) to identify
evidence of causality and the direction
of causal effect.
We investigated the causal effect of
genetically predicted vitamin D levels
on AD risk by deriving a genetic in-
strument of 59 independent SNPs (r2 <
0.001) reported to be most stronglyAbbreviations: 25-OHD, 25-hydroxycholecalciferol;
randomization
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most recent GWAS (N ¼ 443,734)
(Manousaki et al., 2020)
(Supplementary Table S2). Summary
GWAS data were also available for the
most recent AD GWAS meta-analysis
(Paternoster et al., 2015). Two-sample
MR analysis was performed using the
TwoSampleMR R package. A causal
estimate was obtained with the inverse-
variance weighting method by
combining SNP-exposure and SNP-
outcome association in a meta-analysis
assuming multiplicative random effects.
MR-Egger regression, weighted median
analysis, the weighted mode-based es-
timate, and the MR-Pleiotropy Residual
Sum and Outlier method were also
performed to investigate potential hor-
izontal pleiotropy, to ensure that the
genetic instruments only affect the
outcome via the exposure. Horizontal
pleiotropy was also investigated by
performing Causal Analysis Using
Summary Effect Estimates by adopting a
whole-genome approach (Morrison
et al., 2020). There was little evidence
that vitamin D levels causally influence
AD risk (OR per SD change in log-
transformed 25-OHD levels ¼ 1.233;
95% CI ¼ 0.927e1.639; P-value ¼
0.150), consistent with the causal esti-
mate previously reported (Manousaki
et al., 2017).
The causal effect of AD genetic risk
on vitamin D levels was also investi-
gated with an AD instrument of 24
SNPs reported in the most current AD
GWAS (Paternoster et al., 2015)
(Supplementary Table S3). GWAS
summary data from the recent vitamin
D GWAS were made available by the
authors (Manousaki et al., 2020). In the
inverse-variance weighting method,AD, atopic dermatitis; MR, Mendelian
20; corrected proof published online 27 November
ehalf of the Society for Investigative Dermatology.
e (http://creativecommons.org/licenses/by/4.0/).there was strong evidence of AD ge-
netic risk causally increasing log-
transformed 25-OHD concentrations
by 0.043 SD per doubling odds of AD
(95% CI ¼ 0.017e0.069; P-value ¼
0.001) (Figure 1 and Supplementary
Figure S2). Performing the Steiger
directionality test (Hemani et al., 2017)
gave evidence that the variance
explained by the AD genetic instrument
was greater for AD compared with 25-
OHD levels (P-value < 2.2 
1016).However, there was evidence of
heterogeneity (Cochran Q ¼ 282; P-
value < 2.2  1016) and horizontal
pleiotropy (Egger intercept ¼ 0.012;
95% CI ¼ 0.018 to 0.006; P-
value ¼ 5.4  104) in the causal es-
timate (Supplementary Figure S1).
When correcting for detected pleiot-
ropy with the MR-Pleiotropy Residual
Sum and Outlier method, there was still
strong evidence of a causal effect on
25-OHD levels (OR ¼ 0.024; 95% CI ¼
0.012e0.036; P-value ¼ 6.0  104).
Performing Causal Analysis Using
Summary Effect Estimates analysis with
AD and 25-OHD GWAS summary data
also gave evidence of horizontal plei-
otropy (P-valueexpected log pointwise poste-
rior density ¼ 0.13), suggesting that some
AD variants influence 25-OHD levels
via a shared pathway (Morrison et al.,
2020). This appeared to be mostly
driven by rs61816761, mapping to the
RX501X functional FLG mutation
strongly associated with AD, which was
also found to be strongly associated




S3). Excluding the FLG locus from the
AD instrument still gave evidence of a
causal effect on 25-OHD levels (0.018
SD per doubling odds of AD; 95% CI ¼
0.004e0.031; P-value ¼ 0.008)
(Figure 1). There still remained some
evidence of heterogeneity (Cochran’s
Q ¼ 60, P-value ¼ 2.3  105), but
there was weak evidence of horizontalwww.jidonline.org 1339
Figure 1. MR causal estimates of the effect of genetic risk of AD on vitamin D (25-OHD). An AD
instrument comprising all 24 GWAS SNPs, an AD instrument excluding the FLG R501X functional
mutation, and an AD instrument of the FLG R501X functional mutation alone were used. 25-OHD, 25-
hydroxycholecalciferol; AD, atopic dermatitis.
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1340pleiotropy (Egger intercept ¼ 0.001;
95% CI ¼ 0.005 to 0.006; P-value ¼
0.782) (Supplementary Figure S4). We
explored if the causal relationship
detected was limited to AD or was an
effect of any inflammatory disease on
vitamin D levels. MR analyses were
performed to estimate the causal effect
of various inflammatory traits on
vitamin D levels with genetic in-
struments (SNPs with P < 5  108)
derived from individuals of white Eu-
ropean ancestry for asthma (Demenais
et al., 2018), rheumatoid arthritis
(Okada et al., 2014), systemic lupus
erythematosus (Bentham et al., 2015),
psoriasis (Tsoi et al., 2017), type 1
diabetes mellitus (Onengut-Gumuscu
et al., 2015), multiple sclerosis
(International Multiple Sclerosis
Genetics Consortium et al., 2013),
Crohn’s Disease, and ulcerative colitis
(de Lange et al., 2017) (Supplementary
Tables S1 and S4eS11). The asthma
instrument was filtered to exclude SNPs
with nominal association with AD (P <
0.05). We found some evidence of type
1 diabetes mellitus genetic risk
decreasing 25-OHD levels (0.004 SD
per doubling odds of disease; 95%
CI ¼ 0.007 to 0.000; P-value ¼
0.044) and evidence of a causal in-
crease with systemic lupus erythema-
tosus genetic risk (0.003 SD per
doubling odds of disease; 95% CI ¼
0.000e0.005; P-value ¼ 0.017)
(Supplementary Figure S5). Although
these estimates do not pass the
threshold for multiple testing (0.006),
they may warrant further investigation.
For the remaining inflammatory traits
investigated, there was very little evi-
dence to suggest a causal effect on 25-
OHD levels (Supplementary Figure S5).
A genetic risk score for AD was
tested in UK Biobank for association
with potential confounders. Regression
analyses detected weak associations
between the AD genetic risk score andJournal of Investigative Dermatology (2021), Volumlower body mass index and educational
attainment (proxy for socioeconomic
status); however, these estimates are of
a small magnitude and unlikely to
impact the casual effect of AD genetic
risk on 25-OHD levels (Supplementary
Figure S6).
In this study, we have found evidence
that AD is causally associated with an
increase in serum vitamin D levels. This
is not consistent with observational re-
ports of patients with AD with lower
vitamin D levels (Palmer, 2015) and
suggests that the true nature of the
relationship may have been masked by
confounders with opposing effects on
vitamin D and AD such as obesity, so-
cioeconomic status, pollution, and
latitude (Mesquita et al., 2013).
Notably, higher body mass index has
been found to be causally associated
with increased AD risk but lower 25-
OHD levels (Budu-Aggrey et al.,
2019; Vimaleswaran et al., 2013). Our
findings also provide further evidence
that vitamin D supplementation is un-
likely to be an effective treatment for
AD.
Although the AD-associated FLG
gene has a particularly strong relation-
ship with vitamin D, other AD SNPs
show a consistent direction of effect
when omitting this locus, suggesting
that AD more generally influences
serum vitamin D levels. The substantial
heterogeneity and evidence of hori-
zontal pleiotropy observed when
including the FLG locus in the AD in-
strument suggests a direct influence of
FLG on vitamin D that bypasses AD. A
link between FLG and vitamin D has
been previously reported in the same
direction that we report (Thyssen et al.,
2012). The UVBevitamin D3 hypothe-
sis provides a proposed mechanism for
this, whereby trans-urocanic acid, a
breakdown product of FLG, provides
epidermal protection against UVB
(Mildner et al., 2010). Therefore,e 141inheriting an FLG-null mutation (partic-
ularly one that reduces histidine in FLG,
i.e., the R501X truncation reduces FLG
from 413 to 35 histidine residues
[Fauman, 2020]) would result in
increased UV absorption and increased
vitamin D3 synthesis. This mechanism
has been suggested to be advantageous
in northern latitudes, providing an
explanation for the latitude-dependent
gradients of FLG mutation frequency
observed (Thyssen and Elias, 2017), and
warrants future clinical trials of supple-
mentation or phototherapy to investigate
whether different effects are observed in
patients with AD with and without FLG
mutations.
The mechanism explaining the
causal influence of AD on vitamin D is
unclear. This may be explained by
biological effects in the skin similar to
those seen for FLG or behavioral
mechanisms that may alter UV and/or
vitamin exposure in AD sufferers. The
vitamin D GWAS adjusted for vitamin
D supplementation (Manousaki et al.,
2020) but may have included in-
dividuals with AD whose vitamin D
status was raised because of vitamin
Deraising therapy. However, as the UK
Biobank showcase indicates that only
69 of 410,256 participants were recor-
ded to have received phototherapy, this
is unlikely to explain our findings.
In this study, we confirm that there is
weak evidence that vitamin D causally
influences AD. Our findings suggest
that vitamin D supplementation is not
supported as an AD therapy. Further
investigation is required to determine
the mechanisms of the causal effect of
AD genetic risk on serum vitamin D
levels. Stratifying future vitamin D and
phototherapy trials and epidemiolog-
ical analyses by FLG status may assist in
evaluating the contribution of different
mechanisms.
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